×

Galectin-3C combination therapy for human cancer

  • US 9,272,014 B2
  • Filed: 03/29/2012
  • Issued: 03/01/2016
  • Est. Priority Date: 03/29/2011
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical combination having therapeutic synergy comprising:

  • an effective amount of galectin-3C and the proteasome inhibitor bortezomib.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×